The “Heinsberg study” was realised in the municipality of Gangelt (North Rhine-Westphalia) by Prof. Dr. Hendrik Streeck and Prof. Dr. Gunther Hartmann from the University of Bonn and their research team. More than 900 persons were tested for COVID-19, among others using the Anti-SARS-CoV-2 ELISA. The study confirmed the high specificity of the EUROIMMUN ELISA and showed a good correlation with a neutralisation assay.
Quest Diagnostics, one of the largest laboratory chains worldwide is convinced of the good quality of the Anti-SARS-CoV-2 ELISA (IgG) after performing their own validation studies and now uses the EUROIMMN ELISA in the testing of blood samples for infections with SARS-CoV-2 (COVID-19).
Beaumont Health, the largest healthcare provider in Michigan, US, has performed internal validation studies on the EUROIMMUN Anti-SARS-CoV-2 ELISA IgG and now uses it for the most comprehensive serological study in the US. First, 38,000 employees of Beaumont and patients shall be tested. Subsequently, the test systems shall also be provided to other hospitals.
ARUP Laboratories, a leading national reference laboratory in the US with customers all over the country, has been using the Anti-SARS-CoV-2 ELISA (IgG) as a second antibody test for COVID-19 diagnostics since 13th May 2020. “The EUROIMMUN test can also help clinicians understand the level of the antibody response and the duration of long-lasting immunity to the disease” says ARUP’s chief medical officer Julia Delgado in their press release.
On 8th May 2020, Sonora Quest Laboratories, the market share leader in diagnostic laboratory testing in Arizona, announced they have started performing COVID-19 antibody tests. Sonora Quest also opted to use the Anti-SARS-CoV-2 ELISA (IgG). The laboratory stated they will start off by performing approximately 3,000 determinations per day and expand their capacities step by step.
LabCorp, a leading global life sciences company with headquarters in the US, has also opted to use the Anti-SARS-CoV-2 ELISA (IgG) from EUROIMMUN and has been offering a “Return to Work” service for employers since 14th May. This includes, among other services, testing for antibodies against the new coronavirus using a kit for at-home sampling by the user (collection of a blood drop from the fingertip) and the subsequent laboratory blood analysis by means of the EUROIMMUN ELISA.
Also Public Health England, an executive agency of the Department of Health and Social Care in the United Kingdom are now applying the EUROIMMUN-Anti-SARS-CoV-2 ELISA (IgG) to monitor the seroprevalence of anti-SARS-CoV-2 antibodies in the British population.
On 4th June, the Indian Council of Medical Research (ICMR), one of the most relevant medical institutions in India and central Institution in the fight against the COVID-19 pandemic, declared that they have validated three test systems for the detection of IgG antibodies against SARS-CoV-2, among others the EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG), and approved them for seroprevalence studies on SARS-CoV-2 in population groups at risk in India.